Should You Buy Pfizer Stock Before Nov. 4?

Pfizer (NYSE: PFE) stock has underperformed, falling 30% over five years and trading at a low 13x P/E, as investors remain hesitant despite recent solid earnings and raised guidance, citing patent cliffs, long-term growth questions, and healthcare policy uncertainty. While its upcoming Q3 earnings report is unlikely to be a significant short-term catalyst given broader market caution on the sector, the company's strong recent financial performance, including 10% top-line and 30% adjusted earnings growth last quarter, coupled with its low valuation, may offer a compelling long-term opportunity for patient investors despite ongoing industry headwinds.

Analysis

Pfizer (NYSE: PFE) has significantly underperformed, with its stock declining nearly 30% over the past five years and trading at a P/E multiple of 13x compared to the S&P 500's 25x. This persistent discount stems from investor concerns regarding patent cliffs and long-term growth prospects. The broader healthcare sector (XLV) also reflects caution, up only 5% year-to-date 2025 against the S&P 500's 15% gain, influenced by policy uncertainties.

Despite stock struggles, Pfizer reported robust operational results, including 10% top-line growth and a 30% increase in adjusted earnings last quarter, and raised guidance in August. However, these positive fundamentals are overshadowed by industry-wide pressures, such as government initiatives to lower drug prices and tariffs, which Pfizer addressed with a "landmark agreement" and a $70 billion R&D commitment in the U.S. These macro factors contribute to investor hesitancy.

The upcoming Q3 earnings report on November 4th is unlikely to serve as a significant short-term catalyst for PFE, given prevailing cautious investor sentiment towards healthcare stocks. While Pfizer is actively building its pipeline and investing in growth, these initiatives require time to materialize. Historically, strong clinical trial results, rather than earnings reports, have been the primary drivers for pharmaceutical stock rallies.

Despite near-term headwinds and lack of immediate catalysts, Pfizer's current low valuation and strong underlying business performance present a potential long-term opportunity. The company's recent growth in revenue and earnings suggests its discount is more market and industry-driven than fundamental weakness. Patient, long-term investors may find the current entry point attractive.

Key Decisions for Investors

• Investors should monitor Pfizer's Q3 earnings for any material changes in guidance or pipeline developments, while acknowledging that this report is unlikely to be a significant short-term catalyst.
• Long-term investors may consider Pfizer's current low valuation (13x P/E) and recent strong operational performance (10% revenue, 30% adjusted earnings growth) as a potential entry point, viewing the stock as a value opportunity rather than a trap.
• Be cognizant of persistent industry-wide regulatory pressures and tariff uncertainties impacting the broader healthcare sector, which could continue to temper Pfizer's short-term stock performance.